PYLERA
LOE Approachingbismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride
NDAORALCAPSULE
Approved
Sep 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYLERA is a fixed-dose oral capsule combination of bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride approved in 2006 for H. pylori eradication. This triple-therapy antimicrobial targets H. pylori infection through synergistic mechanisms across three distinct drug classes. The combination is designed to reduce pill burden and improve treatment compliance in patient populations requiring gastroenterological intervention.
$2.0MPart D
LOE ApproachingDeclining
With LOE approaching and modest Part D spending of $2M from 2,120 claims in 2023, this brand is in managed decline with a lean commercial infrastructure.
Mechanism of Action
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only 1 linked job currently exists for PYLERA, concentrated in IT/Technician I roles rather than traditional commercial or medical affairs positions. Working on PYLERA offers minimal career momentum given its LOE-approaching lifecycle stage and low commercial velocity.
Technician I
IT
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.